Inclusion criteria:
Adults aged 18 to 75 years with histopathologically confirmed cancer
A history of receiving at least one course of chemotherapy containing a taxane (such as paclitaxel or docetaxel) or a platinum-based agent (such as cisplatin, carboplatin, or oxaliplatin); at least 6 months must have elapsed since the last dose of neurotoxic chemotherapy (taxane or platinum-based agent), and the patient must not currently be receiving neurotoxic chemotherapy.
Confirmation of neuropathic pain with a DN4 score ≥ 4.
Distal and symmetrical symptoms (in the hands and/or feet) accompanied by positive sensory symptoms (paresthesia, allodynia, painful dysesthesia), confirmed through a clinical examination by a specialist in physical medicine and rehabilitation, as well as by EMG-NCS.
The symptoms must have begun during the chemotherapy itself, or at most within 6 months thereafter, and must have persisted for at least 1 month.
Stable dosage of medications for neuropathic pain (such as duloxetine or gabapentinoids) from at least 3 weeks prior to the start of the study through the end of week 24.
Ability to understand the study process and sign informed consent
Exclusion criteria:
Neuropathies resulting from non-chemotherapy-related causes (e.g., neuropathy associated with uncontrolled diabetes, vitamin B12 deficiency, HIV-associated neuropathy), radiculopathy, or central pain syndromes.
Prior receipt of botulinum toxin (any serotype) within the past 6 months, or a known hypersensitivity to the components of BoNT.
Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome), clinically significant generalized weakness.
Current use of systemic corticosteroids or immunosuppressive drugs.
Pregnancy/Breastfeeding
Active infection, uncontrolled lymphedema, or skin damage in the limbs intended for injection.
Planning for the initiation or modification of systemic medications for CIPN during the study.
Coagulation disorders (platelet count < 75 × 10⁹/L) or anticoagulant therapy that cannot be safely discontinued for the purpose of administering injections.
Life expectancy <12 months due to cancer recurrence or other comorbidities.
Cognitive impairment that prevents responding to questionnaires